Want to see REVB full AI Analyst Report?
REVB Stock Chart & Stats
$1.06
$0.04(3.50%)
At close: 4:00 PM EDT
$1.06
$0.04(3.50%)
Day’s Range― - ―
52-Week Range$0.88 - $11.72
Previous CloseN/A
Volume6.03K
Average Volume (3M)740.56K
Market Cap
$4.42M
Enterprise Value-$6.80
Total Cash (Recent Filing)$11.48M
Total Debt (Recent Filing)$739.92K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 05, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.00
Shares Outstanding3,983,416
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$16.00Price Target Upside1409.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityLow leverage reduces near-term solvency pressure and gives the company more flexibility to fund development. Positive, growing equity also supports the asset base, although continued losses could weaken this position through future financing needs.
Clinical Development ProgressSelecting an experienced global CRO is a concrete step toward advancing Gemini into a later-stage study. Execution of the Titan trial could improve clinical validation and future partnering or commercialization prospects if results support efficacy.
Executive Retention AlignmentMilestone-linked awards may align senior management with longer-term company development and value creation. Retaining experienced leadership is particularly important for a small clinical-stage biotechnology company progressing a pivotal pipeline program.
Bears Say
No Revenue And Persistent LossesZero revenue confirms that REVB remains pre-commercial and dependent on future clinical success before building a recurring business. Persistent losses also limit visibility into margins, profitability, and the ability to self-fund development.
Sustained Cash BurnOngoing cash consumption means REVB will likely require external financing to maintain research and clinical programs. Repeated funding needs can pressure shareholders through dilution and make the company vulnerable if capital markets become less accessible.
Reverse-Split Capital Structure RiskBroad reverse-split authority signals pressure around maintaining an effective share structure and preserving financing flexibility. While it does not change operating performance, it highlights capital-structure risk alongside the company’s continuing need for funding.
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $0.88 and its highest was $11.72 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $4.42M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is Nov 05, 2026 which is in 76 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on Aug 06, 2026. The company reported -$0.87 earnings per share for the quarter, beating the consensus estimate of -$0.875 by $0.005.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Undervalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -0.88.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 3,983,416 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$0.87 in its last earnings report, beating expectations of -$0.875. Following the earnings report the stock price went up 1.786%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revelation Biosciences
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
REVB Stock 12 Month Forecast
Average Price Target
$16.00
▲(1409.43% Upside)
Technical Analysis
GT Biopharma
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
21.51% Insiders
0.68% Mutual Funds
5.29% Other Institutional Investors
72.53% Public Companies and
Individual Investors